Bayer’s Xarelto Helped Survival After Heart Attack: Study
This article is for subscribers only.
Patients who took Bayer AG and Johnson & Johnson’s Xarelto with blood-thinning treatment after a severe heart attack had a better chance of surviving without another attack or stroke compared with placebo, a study found.
The 7,817 patients studied had a more serious type of heart attack that is typically caused by a blood clot completely blocking the coronary artery, leading to damage and the death of heart muscle. The treatment period was 24 months.